Literature DB >> 8491239

Single dose pharmacokinetics of proguanil and its metabolites in pregnancy.

J Wangboonskul1, N J White, F Nosten, F ter Kuile, R R Moody, R B Taylor.   

Abstract

Plasma and whole blood concentrations of proguanil, its active metabolite cycloguanil, and the inactive metabolite 4-chlorophenyl-biguanide, were measured by HPLC in 10 healthy Karen women in the last trimester of pregnancy, following a 200 mg single oral dose of proguanil. Four of these women were restudied 2 months after delivery. The pharmacokinetic properties of proguanil were similar during and after pregnancy. Median peak plasma concentrations of proguanil during pregnancy and following delivery were 212 and 215 ng.ml-1, and occurred at 4.5 and 5 h, respectively. Mean plasma AUC values for proguanil during and following pregnancy were 94 and 98 ng.h.ml-1.kg-1, respectively. Corresponding whole blood AUC values were 361 and 396 ng.h.ml-1.kg-1. The mean elimination half lives and mean residence times of proguanil in plasma and whole blood were 12.3 and 19.6 h and 13.8 and 20.7 h respectively during pregnancy. Following pregnancy these values were 17.1 and 19.7 h for plasma and 19.7 h and 20.2 h for whole blood respectively. Mean peak plasma and whole blood concentrations of cycloguanil following pregnancy were 25 and 22 ng.ml-1 respectively. During pregnancy peak cycloguanil concentrations in both plasma and whole blood were markedly lower, 13 and 12 ng ml-1, respectively. Two pregnant women (neither of whom were restudied) were probably poor metabolisers of proguanil. The mean ratio of proguanil to cycloguanil plasma AUC was 16.7 in the third trimester of pregnancy and 7.8 following pregnancy, compared with less than 5 in previously reported studies.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491239     DOI: 10.1007/BF00271366

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism.

Authors:  N A Helsby; S A Ward; G Edwards; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

2.  Determination of proguanil and its metabolites cycloguanil and 4-chlorophenylbiguanide in plasma, whole blood and urine by high-performance liquid chromatography.

Authors:  R B Taylor; R R Moody; N A Ochekpe
Journal:  J Chromatogr       Date:  1987-05-15

3.  Mephenytoin hydroxylase activity in human liver: inhibition by steroids.

Authors:  M Jurima; T Inaba; W Kalow
Journal:  Drug Metab Dispos       Date:  1985 Nov-Dec       Impact factor: 3.922

4.  The pharmacokinetics of proguanil in human subjects following a single oral dose.

Authors:  E M Chiluba; K A Fletcher; A H Price
Journal:  Afr J Med Med Sci       Date:  1987-03

5.  In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.

Authors:  N A Helsby; S A Ward; R E Howells; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

6.  Steady-state kinetics of proguanil and its active metabolite, cycloguanil, in man.

Authors:  M D Edstein; J R Veenendaal; H V Scott; K H Rieckmann
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

7.  A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil.

Authors:  W M Watkins; J D Chulay; D G Sixsmith; H C Spencer; R E Howells
Journal:  J Pharm Pharmacol       Date:  1987-04       Impact factor: 3.765

8.  The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism--a panel study.

Authors:  S A Ward; N A Helsby; E Skjelbo; K Brøsen; L F Gram; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

9.  Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.

Authors:  M Jurima; T Inaba; D Kadar; W Kalow
Journal:  Br J Clin Pharmacol       Date:  1985-04       Impact factor: 4.335

10.  Malaria during pregnancy in an area of unstable endemicity.

Authors:  F Nosten; F ter Kuile; L Maelankirri; B Decludt; N J White
Journal:  Trans R Soc Trop Med Hyg       Date:  1991 Jul-Aug       Impact factor: 2.184

View more
  16 in total

1.  Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling.

Authors:  Khaled Abduljalil; Penny Furness; Trevor N Johnson; Amin Rostami-Hodjegan; Hora Soltani
Journal:  Clin Pharmacokinet       Date:  2012-06-01       Impact factor: 6.447

Review 2.  The safety of antimalarial drugs in pregnancy.

Authors:  P A Phillips-Howard; D Wood
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

3.  The pharmacokinetics and pharmacodynamics of atovaquone and proguanil for the treatment of uncomplicated falciparum malaria in third-trimester pregnant women.

Authors:  K Na-Bangchang; C Manyando; R Ruengweerayut; D Kioy; M Mulenga; G B Miller; J Konsil
Journal:  Eur J Clin Pharmacol       Date:  2005-07-23       Impact factor: 2.953

Review 4.  A Review of Pharmacogenetics of Antimalarials and Associated Clinical Implications.

Authors:  Hazem Elewa; Kyle John Wilby
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 5.  Methods to study mechanisms underlying altered hepatic drug elimination during pregnancy.

Authors:  Hyunyoung Jeong; Catherine S Stika
Journal:  Semin Perinatol       Date:  2020-01-25       Impact factor: 3.300

Review 6.  Pharmacokinetics of antimalarials in pregnancy: a systematic review.

Authors:  Kyle J Wilby; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

7.  Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.

Authors:  Ramatoulie E Janha; Fatoumatta Sisay-Joof; Majidah Hamid-Adiamoh; Archibald Worwui; Hannah L Chapman; Hyginus Opara; Sam Dunyo; Paul Milligan; Kirk Rockett; Peter Winstanley; Munir Pirmohamed; Ann K Miller; David J Conway; Robert T Walton
Journal:  Pharmacogenomics       Date:  2009-09       Impact factor: 2.533

8.  Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.

Authors:  J M Hoskins; G M Shenfield; A S Gross
Journal:  Br J Clin Pharmacol       Date:  1998-11       Impact factor: 4.335

9.  Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil.

Authors:  R McGready; K Stepniewska; E Seaton; T Cho; D Cho; A Ginsberg; M D Edstein; E Ashley; S Looareesuwan; N J White; F Nosten
Journal:  Eur J Clin Pharmacol       Date:  2003-08-30       Impact factor: 2.953

10.  Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania.

Authors:  Theonest K Mutabingwa; Kandi Muze; Rosalynn Ord; Marnie Briceño; Brian M Greenwood; Chris Drakeley; Christopher J M Whitty
Journal:  PLoS One       Date:  2009-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.